A Uniquely Scalable Approach to Sequence Tens of Millions of Single Cells Without Compromising Performance
A Uniquely Scalable Approach to Sequence Tens of Millions of Single Cells Without Compromising Performance
批准号:
10700398
负责人:
Philipp Stefan Spuhler
金额:
$27.56万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
已结题
起止时间:
2023-08-01 至 2024-07-31
关键词:
AccelerationAdoptionAftercareAntibodiesAuthorization documentationBar CodesBarberingCAR T cell therapyCRISPR screenCRISPR/Cas technologyCell SizeCell SurvivalCell TherapyCellsCellular immunotherapyClonal ExpansionClustered Regularly Interspaced Short Palindromic RepeatsDNA sequencingDevelopmentDiseaseDisease remissionDoctor of PhilosophyDropsEncapsulatedEngineeringEvaluationFundingGenerationsGenesGenomeGenome engineeringGoalsGovernmentGrantImmuneImmune responseImmunologic ReceptorsImmunotherapyIndividualJurkat CellsK562 CellsLabelMarketingMethodsMicrofluidicsNoiseOilsPathogenesisPathway interactionsPatient MonitoringPatientsPerformancePersonsPharmaceutical PreparationsPhenotypePopulationPricePropertyResearch PersonnelRoleSamplingSignal TransductionSmall Business Innovation Research GrantSpeedSystemT-Cell ReceptorTestingTranslational ResearchVariantWaterWorkadaptive immune responseauthoritycellular engineeringcombinatorialcommercial launchcostdroplet sequencingexperimental studyexpirationgenome-wideimprovedindexinginnovationmeternanoDropletnext generationoperationprototyperesponsescale upsequencing platformsingle cell analysissingle cell sequencingsuccesstechnology developmenttool developmenttreatment response
中文摘要
免疫疗法(包括CAR-T细胞疗法)在起作用时是神奇的药物,但是
英文摘要
Immunotherapies (including CAR-T cell therapies) are wonder drugs when they work, but the
response rates of today’s immunotherapies are only 15-20% and therapy costs remain
prohibitively high for mass adoption. Recent advances in single cell sequencing make it a critical
tool for the development of next generation cell therapies through high impact applications such
as TCR immune profiling and pooled CRISPR screening. Unlocking the value of these
applications requires interrogation of >10 million cells per experiment. Expiration of Illumina’s core
IP in 2023 re-ignited competition in US & EU markets and re-accelerated the drop in DNA
sequencing costs to make sequencing of ~10 million cells affordable in 1-2 years, but existing
methods for single cell barcoding do not support throughput beyond 1 million cells per experiment.
Proposed alternatives are scalable, but trade-offs in performance and ease-of-use make them
unsuitable for translational research. Sansimeon’s approach uniquely enables scaled single cell
sequencing with throughput to 100M cells, while retaining high ease-of-use and necessary cell
capture efficiency for high-throughput applications in translational research. The platform
overcomes throughput limitations common to other drop-seq approaches by leveraging rapid
deterministic pairing of single cells with single beads in a microchannel prior to emulsification,
without the need for multi-step labeling workflows such as cell-hashing or combinatorial indexing.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金